Biologics and Behcet's: Disease diversity and trial design

Ocular Immunology and Inflammation

Volumn 15, Issue 2, 2007, Pages 61-62

  Rosenbaum, James T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DACLIZUMAB; INFLIXIMAB;

BEHCET DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; EDITORIAL; HUMAN; NONHUMAN; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; UVEITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS;

EID: 34250164211     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940701357756     Document Type: Editorial

References (9)

1. Mamo JG. The rate of visual loss in Behcet's disease. Archives of Ophthalmology. 1970;84:451-452.
2. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Eng J Med. 1990;322:281-285.
3. Masuda K, Nakajima A, Urayama A, Nakae K, Kogene M, Inaba G. Double masked trial of cyclosporin versus colchicine and long term open study of cyclosporin in Behcet's disease. Lancet. 1989;1:1093.
4. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423-431.
5. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;358:295-296.
6. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:7462-7466.
7. Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology. 2003;110:786-789.
8. Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: A multicenter noncomparative interventional case series. Ophthalmology. 2005;112:764-770.
9. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J.Rheumatol. 2004;31:1362-1368.